E. David Crawford, MD, Philip J. Koo, MD, and David M. Albala, MD, present seven abstracts highlighting PMSA PET imaging and its impact on prostate cancer management.
Phillip J. Koo, MD, leads a panel discussion focused on PSMA PET-CT’s expanding role in prostate cancer screening and diagnosis.
Rafael Sanchez-Salas, MD, reviews data on micro-ultrasound for prostate cancer imaging and assesses its utility in comparison to MRI.
Sangeet Ghai, MD, FRCR, reviews data on micro-ultrasound for PCa imaging and assesses whether it is superior to conventional imaging.
Steven P. Rowe, MD, PhD, explains research supporting the emerging role of PSMA imaging in prostate cancer diagnosis and therapy.
Phillip J. Koo, MD, summarizes talks from a session he moderated on next generation imaging, with a focus on PSMA, during IPCU 31.
Brian T. Helfand, MD, PhD, discusses the efficacy of next generation imaging options for localization of recurrent prostate cancer.
Jelle Barentsz, MD, PhD, discusses recent advancements in PI-RADS and comparative studies of mpMRI and bpMRI.
David M. Albala, MD, discusses theranostics and considers its future role as a form of precision medicine for prostate cancer.
Laurence Klotz, MD, FRCSC, makes a case for MRI-guided transurethral ultrasound ablation (TULSA) in patients with localized prostate cancer.
Peter R. Carroll, MD, MPH, summarizes data on PSMA PET and compares its overall efficacy to conventional imaging at the time of diagnosis.
Steven E. Finkelstein, MD, FACRO, discusses 3 cases of prostate cancer recurrence and their clinical management from a radiation oncology perspective.